Related references
Note: Only part of the references are listed.Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology
Yoichi Naito et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients
Giorgio Scagliotti et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
Hongge Liang et al.
ONCOTARGETS AND THERAPY (2020)
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Juergen Wolf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Multiplex gene-panel testing for lung cancer patients
Yasushi Yatabe et al.
PATHOLOGY INTERNATIONAL (2020)
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium
Robin Guo et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population
Chien-Hung Gow et al.
LUNG CANCER (2017)
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
Thanyanan Reungwetwattana et al.
LUNG CANCER (2017)
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
Joanna H. Tong et al.
CLINICAL CANCER RESEARCH (2016)
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark M. Awad et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations
Xuewen Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
Difan Zheng et al.
ONCOTARGET (2016)
Activation of MET via diverse exon 14 skipping mutations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors
Garrett M. Frampton et al.
CANCER RESEARCH (2015)
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
Paul K. Paik et al.
CANCER DISCOVERY (2015)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Somatic mutations lead to an oncogenic deletion of Met in lung cancer
M Kong-Beltran et al.
CANCER RESEARCH (2006)
Share Paper
